News

Illumina said that the array provides up to 50% more coverage of human genome variation. The Omni2.5 delivers genome coverage for both SNP and copy number variation (CNV)

Mr Weyer will lead Amylin’s R&D organization, focusing on expanding opportunities with the company’s existing diabetes products, advancing the obesity and early diabetes pipeline, and driving research programs

Reportedly, Tetraphase will use the funds to advance its pipeline of antibiotics, into Phase 1 and Phase 2 clinical studies. The company’s TP-434, a broad spectrum intravenous (IV)

Generex has received the patent titled ‘Mixed Micellar Pharmaceutical Delivery System and Method of Preparation’ from The Commissioner of the Japan Patent Office. The patent number 449282 is

Findings from Abraxis BioScience phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab(R)) driven chemotherapy, nab-paclitaxel (Abraxane for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable

For more than 30 years, Accupac has served pharmaceutical and consumer products companies by offering customized contract manufacturing and packaging solutions. Working within an FDA and cGMP environment,

CoaguSense PT/INR monitoring system consists of a low-cost meter and disposable test strip. Medical professionals can order the system through Abbott Point of Care, which formed an exclusive

Mr Davis had previously served as corporate vice president and chief financial officer for Baxter. Concurrent with this change, Robert Hombach has been named corporate vice president and

Martin Gleave, executive director of Vancouver Prostate Centre, said: “Knowing that our two organisations hold similar mandates, this collaboration with CDRD ensures that we are maximising our resources